Related Experiment Video
Updated: Feb 10, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Molecular monitoring of chronic myeloid leukemia: a personalized approach to optimizing treatment response
Linda Nichols1, Julie Pippins2, Lon Castle3
1Department of Clinical Practices & Therapeutics, Express Scripts, 100 Parsons Pond Drive, B3-MS2, Franklin Lakes, NJ 07417, USA. linda@nicholsnet.com.
Abstract:
Personalized medicine is rapidly developing a purposeful niche in the field of oncology. Monitoring the activity of the oncogenic fusion gene BCR-ABL1 in chronic myeloid leukemia (CML) is a good example of individualizing CML treatment for patients using patient-specific genetic information. However, the frequency at which molecular monitoring for BCR-ABL1 transcripts occurs during treatment with tyrosine kinase inhibitors (TKIs) for CML in clinical practice is much lower than that recommended by either the National Cancer Center Network or the European LeukemiaNet guidelines. Adherence, one of the most critical factors affecting response to TKIs, is often less than desirable and rarely communicated to physicians by patients or managed by care providers. Less than optimal molecular monitoring and low adherence to TKI treatment can lead to rising transcripts levels, that when not detected, have been shown to contribute to poor outcomes. This review reports the basis for and describes the design of a state-of-the-art program intended to improve communication with physicians through real-time messaging about sequential test results for BCR-ABL1 and patients' adherence to TKI therapy.
Insights
Monitoring chronic myeloid leukemia (CML) requires tracking BCR-ABL1 gene activity. This study introduces a program to improve communication about molecular monitoring and adherence to tyrosine kinase inhibitor (TKI) therapy for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Personalized medicine is advancing oncology treatments.
- Monitoring BCR-ABL1 fusion gene activity is key for individualizing chronic myeloid leukemia (CML) treatment.
- Current molecular monitoring frequency for BCR-ABL1 in CML patients on tyrosine kinase inhibitors (TKIs) is below recommended guidelines.
Purpose of the Study:
- To address suboptimal molecular monitoring and low adherence in CML patients undergoing TKI therapy.
- To design a program for real-time communication between patients and physicians regarding BCR-ABL1 transcript levels and TKI adherence.
Main Methods:
- Review of current practices in CML molecular monitoring and TKI adherence.
- Design of a novel program incorporating real-time messaging for sequential BCR-ABL1 test results and adherence data.
- Focus on improving physician communication and patient management.
Main Results:
- Suboptimal molecular monitoring and low TKI adherence can lead to increased BCR-ABL1 transcript levels and poorer patient outcomes.
- The designed program aims to enhance communication regarding critical treatment data.
- Improved communication is expected to facilitate timely interventions and better management of CML.
Conclusions:
- Enhanced communication and monitoring are crucial for optimizing TKI therapy in CML.
- The proposed program offers a state-of-the-art approach to improve patient care by bridging communication gaps.
- Real-time data sharing on BCR-ABL1 levels and adherence can lead to improved outcomes in CML patients.
Related Concept Videos
01:28Maslow's Humanistic Approach on Personality
03:51Molecular Orbital Theory II
02:05Self-Presentation: Self-Monitoring and Self-Handicapping
00:48Optimal Foraging
02:00Molecular Models
01:25Personal Identity